CompareMarketResearchRequest a sample
Home / Healthcare / Inhalation Drug Delivery

Healthcare · Market report

Inhalation Drug Delivery Market Size, Share and Forecast 2026-2036

The global inhalation drug delivery market is worth USD 40.1 bn in 2026 and is forecast to reach USD 68.5 bn by 2036, growing at a 5.5% CAGR. United States is the largest country market and Metered-dose inhalers is the largest by device type segment.

USD 40.1 bnMarket size 2026
USD 68.5 bnForecast 2036
5.5%CAGR 2026-2036
United StatesLargest country

Request a free sample Jump to the forecast

Report price: Starts from USD 1,999

5 segmentation views25 countries2026 to 2036 yearly forecast

Market overview

The global inhalation drug delivery market is worth USD 40.1 bn in 2026 and is forecast to reach USD 68.5 bn by 2036, growing at a 5.5% CAGR. United States is the largest country market and Metered-dose inhalers is the largest by device type segment.

ScopeInhaled drug products and their delivery systems: metered-dose inhalers, dry-powder inhalers, soft-mist inhalers and nebulisers, valued at the sale of the drug-device product to patients and providers.
IndustryHealthcare
Value 2025USD 38.0 bn
Value 2026USD 40.1 bn
Value 2036USD 68.5 bn
CAGR 2026-20365.5%
Volume 20261,462 million units
Volume 20362,261 million units
Average price 2026USD 27.4 per unit
Report priceStarts from USD 1,999
PublishedNovember 2026

Request a free sample of this report

Inhalation Drug Delivery market size and forecast, 2026-2036

Exhibit 1The global inhalation drug delivery market is forecast to grow from USD 40.1 bn in 2026 to USD 68.5 bn by 2036, a rise of 71%Global market value in USD: 2025 base year, 2026 estimate and forecast to 2036. CAGR 2026 to 2036: 5.5%
Inhalation Drug Delivery market value, 2025 to 2036Market value by year. 2025: USD 38.0 bn; 2026: USD 40.1 bn; 2027: USD 42.3 bn; 2028: USD 44.6 bn; 2029: USD 47.1 bn; 2030: USD 49.7 bn; 2031: USD 52.4 bn; 2032: USD 55.3 bn; 2033: USD 58.3 bn; 2034: USD 61.5 bn; 2035: USD 64.9 bn; 2036: USD 68.5 bn. Compound annual growth rate 2026 to 2036: 5.5%.202540.1 bn202652.4 bn203168.5 bn20365.5% CAGR

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

YearMarket value
2026USD 40.1 bn
2027USD 42.3 bn
2028USD 44.6 bn
2029USD 47.1 bn
2030USD 49.7 bn
2031USD 52.4 bn
2032USD 55.3 bn
2033USD 58.3 bn
2034USD 61.5 bn
2035USD 64.9 bn
2036USD 68.5 bn

Inhalation Drug Delivery market segmentation

By device type

Exhibit 2Metered-dose inhalers is the largest segment by device type, with 42.0% of 2026 revenueEstimated share of 2026 global revenue, by device type
Inhalation Drug Delivery market share by device type, 2026Share of 2026 revenue by device type. Metered-dose inhalers: 42.0%; Dry-powder inhalers: 34.0%; Nebulisers: 16.0%; Soft-mist and other inhalers: 8.0%.Metered-dose inhalers42.0%Dry-powder inhalers34.0%Nebulisers16.0%Soft-mist and other inhalers8.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Metered-dose inhalers42.0%38.0%USD 16.8 bn4.5%
Dry-powder inhalers34.0%35.5%USD 13.6 bn6.0%
Nebulisers16.0%15.9%USD 6.4 bn5.5%
Soft-mist and other inhalers8.0%10.5%USD 3.2 bn8.4%

By indication

Exhibit 3COPD adds the most revenue by indication, growing from USD 16.0 bn in 2026 to USD 26.9 bn by 2036Estimated revenue in USD by indication, 2026 and 2036 forecast
Inhalation Drug Delivery market by indication, 2026 and 2036Revenue by indication in 2026 and 2036. COPD: USD 16.0 bn in 2026, USD 26.9 bn in 2036, change +68%; Asthma: USD 15.2 bn in 2026, USD 23.2 bn in 2036, change +52%; Systemic and other inhaled drugs: USD 5.6 bn in 2026, USD 12.5 bn in 2036, change +122%; Cystic fibrosis and other respiratory: USD 3.2 bn in 2026, USD 5.9 bn in 2036, change +84%.20262036 forecastChangeCOPD+68%16.0 bn26.9 bnAsthma+52%15.2 bn23.2 bnSystemic and other inhaled drugs+122%5.6 bn12.5 bnCystic fibrosis and other respiratory+84%3.2 bn5.9 bn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Asthma38.0%33.9%USD 15.2 bn4.3%
COPD40.0%39.3%USD 16.0 bn5.3%
Cystic fibrosis and other respiratory8.0%8.6%USD 3.2 bn6.3%
Systemic and other inhaled drugs14.0%18.2%USD 5.6 bn8.3%

By drug class

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Beta-agonists28.0%26.0%USD 11.2 bn4.7%
Inhaled corticosteroids22.0%20.0%USD 8.8 bn4.5%
Combination therapies32.0%34.0%USD 12.8 bn6.1%
Antibiotics and other inhaled drugs18.0%20.0%USD 7.2 bn6.6%

By age group

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Adults under sixty-five52.0%50.0%USD 20.8 bn5.1%
Seniors30.0%32.0%USD 12.0 bn6.2%
Children18.0%18.0%USD 7.2 bn5.5%

By distribution

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Retail pharmacy48.0%44.0%USD 19.2 bn4.6%
Hospital pharmacy28.0%26.0%USD 11.2 bn4.7%
Online and mail order24.0%30.0%USD 9.6 bn7.9%

Top 25 countries for inhalation drug delivery by revenue

Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 82.5% of 2026 revenue and the 25 countries below together hold 95.1%.

Exhibit 4United States is the largest country market at USD 18.0 bn in 2026, and the three largest countries hold 59.0% of global revenueEstimated 2026 revenue in USD and share of the global market, ten largest countries
Inhalation Drug Delivery market, ten largest countries in 2026Ten largest countries by 2026 revenue. United States: USD 18.0 bn, 45.0%; China: USD 3.2 bn, 8.0%; Japan: USD 2.4 bn, 6.0%; Germany: USD 2.0 bn, 5.0%; United Kingdom: USD 1.6 bn, 4.0%; France: USD 1.6 bn, 4.0%; Italy: USD 1.2 bn, 3.0%; Canada: USD 1.2 bn, 3.0%; Spain: USD 1.0 bn, 2.5%; Brazil: USD 802 mn, 2.0%.United States18.0 bn 45.0%China3.2 bn 8.0%Japan2.4 bn 6.0%Germany2.0 bn 5.0%United Kingdom1.6 bn 4.0%France1.6 bn 4.0%Italy1.2 bn 3.0%Canada1.2 bn 3.0%Spain1.0 bn 2.5%Brazil802 mn 2.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

#CountryValue 2026Share 2026Value 2036CAGR 2026-36
1United StatesUSD 18.0 bn45.0%USD 31.2 bn5.6%
2ChinaUSD 3.2 bn8.0%USD 5.5 bn5.6%
3JapanUSD 2.4 bn6.0%USD 3.6 bn4.2%
4GermanyUSD 2.0 bn5.0%USD 3.2 bn4.6%
5United KingdomUSD 1.6 bn4.0%USD 2.7 bn5.2%
6FranceUSD 1.6 bn4.0%USD 2.5 bn4.7%
7ItalyUSD 1.2 bn3.0%USD 1.9 bn4.8%
8CanadaUSD 1.2 bn3.0%USD 2.0 bn5.1%
9SpainUSD 1.0 bn2.5%USD 1.6 bn5.1%
10BrazilUSD 802 mn2.0%USD 1.6 bn7.0%
11IndiaUSD 682 mn1.7%USD 1.6 bn9.2%
12AustraliaUSD 545 mn1.4%USD 877 mn4.9%
13South KoreaUSD 409 mn1.0%USD 657 mn4.9%
14MexicoUSD 409 mn1.0%USD 822 mn7.2%
15RussiaUSD 341 mn0.8%USD 548 mn4.9%
16TurkeyUSD 341 mn0.8%USD 685 mn7.2%
17NetherlandsUSD 341 mn0.8%USD 548 mn4.9%
18PolandUSD 273 mn0.7%USD 438 mn4.9%
19Saudi ArabiaUSD 273 mn0.7%USD 548 mn7.2%
20SwitzerlandUSD 273 mn0.7%USD 438 mn4.9%
21BelgiumUSD 273 mn0.7%USD 438 mn4.9%
22IndonesiaUSD 273 mn0.7%USD 657 mn9.2%
23ArgentinaUSD 204 mn0.5%USD 329 mn4.9%
24SwedenUSD 204 mn0.5%USD 329 mn4.9%
25TaiwanUSD 204 mn0.5%USD 329 mn4.9%
Rest of worldUSD 2.0 bn4.9%USD 3.4 bn5.5%
Exhibit 5United States and China account for 54% of the USD 28.4 bn the market is forecast to add by 2036Forecast revenue added between 2026 and 2036 by country, in USD
Inhalation Drug Delivery market, where the growth to 2036 comes fromRevenue added between 2026 and 2036. Market value 2026: USD 40.1 bn. United States: +USD 13.1 bn; China: +USD 2.3 bn; Japan: +USD 1.2 bn; Germany: +USD 1.1 bn; United Kingdom: +USD 1.1 bn; 20 other countries: +USD 8.1 bn; Rest of world: +USD 1.4 bn. Market value 2036: USD 68.5 bn.Market value 202640.1 bnUnited States+13.1 bnChina+2.3 bnJapan+1.2 bnGermany+1.1 bnUnited Kingdom+1.1 bn20 other countries+8.1 bnRest of world+1.4 bnMarket value 203668.5 bn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

Competitive landscape

Group 1: Global leaders

  • GSK
  • AstraZeneca
  • Boehringer Ingelheim
  • Chiesi
  • Novartis
  • Teva

Group 2: Regional and specialist players

  • Cipla
  • Viatris
  • PARI
  • Trudell Medical
  • Aptar Pharma
  • Orion Corporation
  • Vectura
  • Hovione
  • Recipharm
  • Omron Healthcare

Group 3: Emerging and niche players

  • Aerogen
  • Lupin
  • Glenmark
  • MannKind
  • Liquidia
  • Bespak
  • Merxin

Research methodology

Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the inhalation drug delivery market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.

The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 5.5% is calculated from the resulting values.

The market is divided by device type, by indication, by drug class, by age group, by distribution. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.

Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.

Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.

Read the full research methodology

Frequently asked questions

How big is the inhalation drug delivery market?

The global inhalation drug delivery market is estimated at USD 38.0 bn in 2025 and USD 40.1 bn in 2026.

How fast will the inhalation drug delivery market grow?

It is forecast to reach USD 68.5 bn by 2036, a compound annual growth rate of 5.5% from 2026, an increase of USD 28.4 bn.

Which country is the largest market for inhalation drug delivery?

United States is the largest market by revenue at USD 18.0 bn in 2026, 45.0% of the global total. The three largest countries together hold 59.0%.

Which country is growing fastest?

Among the ten largest markets, Brazil is growing fastest at 7.0% a year from 2026 to 2036.

Which inhalation drug delivery segment is largest?

In the by device type split, Metered-dose inhalers is the largest segment with 42.0% of 2026 revenue.

Who are the leading inhalation drug delivery companies?

Global leaders include GSK, AstraZeneca, Boehringer Ingelheim, Chiesi.

Need the full report?

Request a sample to see the structure, tables and country detail.

Request a free sample

Related markets in Healthcare

← Infusion Pump Injectable Drug Delivery →

All Healthcare markets →

Request a sample